Covered recipient · General Payments record
MOTHAFFAR F RIMAWI
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$51,292.09
- Reported across 121 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $10,797.50 | 5 |
| Honoraria | $2,520.00 | 1 |
| Travel and Lodging | $965.41 | 2 |
| Food and Beverage | $767.81 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $6,389.39 | 7 |
| PFIZER INC. | $5,579.19 | 5 |
| AstraZeneca UK Limited | $3,022.50 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $59.64 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca UK Limited | $1,387.50 | 01/23/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1093904050 | CMS |
| AstraZeneca UK Limited | $750.00 | 04/30/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1093886912 | CMS |
| AstraZeneca UK Limited | $135.00 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093883425 | CMS |
| AstraZeneca UK Limited | $750.00 | 08/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1093918428 | CMS |
| Gilead Sciences, Inc. | $25.28 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133803006 | CMS |
| Gilead Sciences, Inc. | $6,020.00 | 06/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1133599427 | CMS |
| Gilead Sciences, Inc. | $83.36 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133803008 | CMS |
| Gilead Sciences, Inc. | $17.45 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133803010 | CMS |
| Gilead Sciences, Inc. | $108.96 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133803012 | CMS |
| Gilead Sciences, Inc. | $20.82 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133803014 | CMS |
| Gilead Sciences, Inc. | $113.52 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133803016 | CMS |
| Novartis Pharmaceuticals Corporation | $59.64 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087315683 | CMS |
| PFIZER INC. | $522.45 | 09/06/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1131600907 | CMS |
| PFIZER INC. | $203.78 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131600911 | CMS |
| PFIZER INC. | $442.96 | 09/06/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1131600916 | CMS |
| PFIZER INC. | $2,520.00 | 10/17/2024 | Honoraria | Undisputed | 01/23/2026 | 1131624859 | CMS |
| PFIZER INC. | $1,890.00 | 12/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131240900 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.